Table 1.
Clinical information for liver SBRT studies included in liver toxicity dose-volume analysis
| Investigator | Diagnosis | CP status (%) | Chemotherapy rate (%) | Patients (n) | Toxicity types reported* | Grade ≥3 liver enzyme toxicity rate (n/N; %) | General GI toxicity† rate (n/N; %)
|
|
|---|---|---|---|---|---|---|---|---|
| Grade ≥2 | Grade ≥3 | |||||||
| Barney et al (24), 2012 | IHC | NA | 89 | 9 | Liver failure, general GI | NA | 6/9 (67) | 0/9 (0) |
| Tse et al (13), 2008 | HCC or IHC | CP: A, 100 | 17 | 41 | RILD, liver enzymes, general GI, biochemical changes | 10/41 (24) | 18/41 (44) | 4/41 (10) |
| Vautravers- Dewas et al (25), 2011 | Mets | NA | 93 | 42 | General GI | NA | 19/42 (45) | 0/42 (0) |
| Huang et al (22), 2012 | Recurrent HCC | CP: A, 78; B, 19; C, 3 | 3 | 36 | General GI | NA | 10/36 (28) | 1/36 (3) |
| Kang et al (21), 2012 | HCC | CP: A, 87; B, 13 | NA | 47 | Biochemical, general GI, CP progression | NA | NA | 5/47 (11) |
| Goodman et al (10), 2010 | HCC, IHC, Mets | CP A, 100 | NA | 26 | Liver enzymes, general GI | 0/26 (0) | 3/26 (12) | 0/26 (0) |
| Lee et al (11), 2009 | Mets | CP: A, 100 | 87 | 68 | Liver enzymes, biochemical, RILD, general GI | 2/68 (3) | 30/68 (44) | 5/68 (7) |
| Andolino et al (14), 2011 | Primary HCC | CP: A, 60; B, 40 | NA | 56 | Liver enzymes, general GI, biochemical, CP progression | 2/56 (4) | 13/56 (23) | NA |
| Bujold et al (12), 2013 | HCC | CP: A, 100 | NA | 102 | Liver enzymes, biochemical, general GI, CP progression | 11/102 (11) | NA | 4/102 (4) |
| Son et al (20), 2010 | Primary HCC | CP: A, 89; B, 8; C, 3 | 3 | 36 | Liver enzymes, CP progression | 2/36 (6) | NA | NA |
| Barney et al (26), 2013 | IHC, HCC, Mets | NA | “Most” | 43 | General GI | NA | NA | 5/43 (12) |
| Bae et al (23), 2013 | HCC | CP: A, 91; B, 9 | 6 | 35 | Liver enzymes, general GI | 3/35 (9) | NA | 5/35 (14) |
Abbreviations: CP = Child-Pugh; HCC = hepatocellular carcinoma; IHC = intrahepatic cholangiocarcinoma; Mets = metastases; NA = not available.
*
All toxicity types reported in the studies, including toxicities not used for modeling in our work; toxicities used for modeling included liver enzymes and general GI and those reported but not used for modeling because of limited data included liver failure, CP status decline, and biochemical endpoints.
†
General GI toxicities were defined as fatigue, nausea, diarrhea, gastritis, ulcers, GI area pain, and colitis.